Effectiveness and Safety of Apixaban Versus Warfarin in
VTE Patients With Obesity and Morbid Obesity
Cohen A, Sah J, Lee T, Rosenblatt L, Hlavacek P, Emir B, Keshishian A, Yuce H, and Luo X.
Objective: To evaluate the risk of recurrent VTE, major bleeding, and CRNM
bleeding in VTE patients initiating apixaban or warfarin, stratified by obesity*,†,‡
bleeding in VTE patients initiating apixaban or warfarin, stratified by obesity*,†,‡